TG Therapeutics, Inc.
NASDAQ:TGTXBiotechnology
+$1.03 today
- Market cap
- $9.99B
- Beta
- 1.68
- P/E (TTM)
- 16.4
- EPS (TTM)
- $3.20
Volume 1.87M
Average 2.15M
TGTX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
TG Therapeutics, Inc.NASDAQ: TGTX
Total Equity · Q3 FY2026 · quarter ended Sep 2026
Total equity falls 5.8% from a year ago
Total equity stood at $572.13M at the end of Q3 FY2026, down 5.8% from a year earlier and down 5.3% from the prior quarter. Over 3 fiscal years it compounded at +122.8% a year.
Context
- Total equity amounted to 35.9% of total assets at the end of Q3 FY2026, down 23.3 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -5.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 648.02M USD
- Year-over-year change
- +191.4%
- 4-year CAGR
- +28.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 648.02M | +191.4% |
| FY2024 | 2024-12-31 | 222.36M | +38.5% |
| FY2023 | 2023-12-31 | 160.5M | +174.0% |
| FY2022 | 2022-12-31 | 58.59M | -75.3% |
| FY2021 | 2021-12-31 | 237.15M | — |
Total Equity vs competitors
How TGTX compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -5.8% is the 5th highest of 9, against a peer median of -5.2%.
- Total equity amounts to 35.9% of total assets for TGTX, versus a peer median of 58.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.96B USD | +12.4% | -40.2% | 47.6% | |
| Sep 2026 | $649.47M USD | +8.5% | +17.4% | 90.0% | |
| Sep 2026 | $572.13M USD | -5.8% | +122.8% | 35.9% | |
| Jun 2026 | $503.23M USD | -18.9% | -4.4% | 69.4% | |
| Mar 2026 | $240.68M USD | +387.9% | +2.9% | 95.1% | |
| Dec 2025 | $35.35M USD | -30.0% | -24.8% | 45.2% | |
| Mar 2026 | $21.2M USD | -73.2% | -26.8% | 9.7% | |
| Dec 2025 | -€21.69M EUR | -345.6% | — | 34.6% | |
| Mar 2026 | -$216.38M USD | +9.2% | — | 74.2% | |
| Peer median (excluding TGTX) | — | -5.2% | -14.6% | 58.5% | |
Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 298.89M | 102.3M | 92.93M | 179.89M | 79.15M |
| Short-term Investments | 15.88M | 59.37M | 124.58M | 131.11M | 62.82M |
| Net Receivables | 1.39M | 0 | 51.09M | 129.19M | 305.63M |
| Inventory | 0 | 0 | 39.82M | 110.46M | 125.59M |
| Other Current Assets | 2.88M | 2.36M | 5.34M | 15.72M | 57.58M |
| Total Current Assets | 330.97M | 168.27M | 317.94M | 566.36M | 630.76M |
| Property, Plant & Equipment (Net) | 11.07M | 10.82M | 8.15M | 7.15M | 6.28M |
| Goodwill | 799K | 799K | 799K | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 35.53M | 12.4M | 1.29M | 808K | 59.14M |
| Tax Assets | 0 | 0 | 0 | 0 | 348M |
| Other Non-current Assets | 1.26M | 1.27M | 1.42M | 3.37M | 19.08M |
| Total Non-current Assets | 48.66M | 25.3M | 11.64M | 11.33M | 432.49M |
| Total Assets | 379.63M | 193.57M | 329.59M | 577.69M | 1.06B |
| Account Payables | 0 | 0 | 0 | 0 | 107.51M |
| Short-term Debt | 975K | 0 | 0 | 0 | 1.04M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 152K | 11.41M | 21.23M |
| Other Current Liabilities | 62.97M | 51.62M | 52.12M | 78.11M | 23.97M |
| Total Current Liabilities | 65.38M | 53.2M | 53.72M | 90.68M | 153.76M |
| Long-term Debt | 66.79M | 71.14M | 100.12M | 244.43M | 252.67M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 457K | 305K | 6.02M | 12.09M | 8.81M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (7.02M) |
| Total Non-current Liabilities | 77.09M | 81.78M | 115.37M | 264.65M | 261.47M |
| Total Liabilities | 142.48M | 134.99M | 169.09M | 355.33M | 415.23M |
| Common Stock | 143K | 146K | 151K | 156K | 159K |
| Retained Earnings | (1.33B) | (1.53B) | (1.55B) | (1.53B) | (1.08B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 237.15M | 58.59M | 160.5M | 222.36M | 648.02M |
| Total Debt | 79.05M | 83.06M | 110.8M | 253.72M | 260.73M |
| Net Debt | (219.84M) | (19.24M) | 17.86M | 73.83M | 181.58M |
TG Therapeutics, Inc.
NASDAQ:TGTX
Intrinsic Alpha fair value
Locked
Current Price
$66.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.